Literature DB >> 7661290

Breast cancer in young patients.

J Sariego1, S Zrada, M Byrd, T Matsumoto.   

Abstract

BACKGROUND: Breast cancer in a young person is considered by many to be a rare and very aggressive disease. Theories regarding the aggressiveness of the disease are varied. This study was undertaken in an attempt to help formulate guidelines regarding screening for and treatment of breast cancer in the young patient. PATIENTS AND METHODS: A retrospective review was undertaken of 81 breast cancer patients aged < or = 35 years who underwent definitive surgical treatment. All patients were treated at a single institution.
RESULTS: Overall 5- and 10-year survival rates were 65% and 49%, respectively. In patients with disease localized to the breast, 5- and 10-year rates were 89% and 78%, respectively. There was no significant difference in survival with respect to age or date of diagnosis, nor was there a difference in cancer stage distribution. The only major determinant of survival was stage at the time of diagnosis.
CONCLUSIONS: We conclude that young age does not seem to be directly related to the "aggressiveness" or "virulence" of breast cancer, especially among patients with localized disease. These results underscore the need for aggressive and early treatment of these patients. The improved survival with early detection is a valid argument for careful screening, even among very young patients.

Entities:  

Mesh:

Year:  1995        PMID: 7661290     DOI: 10.1016/s0002-9610(05)80007-8

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  7 in total

1.  Indian Solutions for Indian Problems-Association of Breast Surgeons of India (ABSI) Practical Consensus Statement, Recommendations, and Guidelines for the Treatment of Breast Cancer in India.

Authors:  S P Somashekhar; Gaurav Agarwal; S V S Deo; P Raghu Ram; Diptendra Sarkar; Vani Parmar
Journal:  Indian J Surg       Date:  2017-06-22       Impact factor: 0.656

2.  The Relationship Between Estrogen Receptor, Progesterone Receptor and Human Epidermal Growth Factor Receptor 2 Expression of Breast Cancer and the Retention Index in Dual Phase (18)F-FDG PET/CT.

Authors:  Hansol Moon; Woo Chul Noh; Hyun-Ah Kim; Eun-Kyu Kim; Ko Woon Park; Seung Sook Lee; Joon Ho Choi; Kyung Woo Han; Byung Hyun Byun; Ilhan Lim; Byung Il Kim; Chang Woon Choi; Sang Moo Lim
Journal:  Nucl Med Mol Imaging       Date:  2016-04-11

3.  Senescence Marker Protein 30 (SMP30): A Novel Pan-Species Diagnostic Marker for the Histopathological Diagnosis of Breast Cancer in Humans and Animals.

Authors:  Su-Min Baek; Seoung-Woo Lee; Tae-Un Kim; Seong-Kyoon Choi; Sungho Yun; Won-Jae Lee; Se-Hyeon Han; Il-Hwa Hong; Sang-Joon Park; Tae-Hwan Kim; Kyu-Shik Jeong; Jin-Kyu Park
Journal:  Int J Mol Sci       Date:  2021-02-26       Impact factor: 5.923

4.  Do younger women with non-metastatic and non-inflammatory breast carcinoma have poor prognosis?

Authors:  Aleyamma Mathew; Manoj Pandey; Balakrishnan Rajan
Journal:  World J Surg Oncol       Date:  2004-01-22       Impact factor: 2.754

5.  Age at diagnosis of female breast cancer in Oman: Issues and implications.

Authors:  Itrat Mehdi; Essam Abdul Monem; Bassim Jaffar Al Bahrani; Suad Al Kharusi; Ayman Mohammad Nada; Jawad Al Lawati; Najla Al Lawati
Journal:  South Asian J Cancer       Date:  2014-04

6.  The associations between immunity-related genes and breast cancer prognosis in Korean women.

Authors:  Jaesung Choi; Nan Song; Sohee Han; Seokang Chung; Hyuna Sung; Ji-young Lee; Sunjae Jung; Sue K Park; Keun-Young Yoo; Wonshik Han; Jong Won Lee; Dong-Young Noh; Daehee Kang; Ji-Yeob Choi
Journal:  PLoS One       Date:  2014-07-30       Impact factor: 3.240

7.  Factors affecting the number of sentinel lymph nodes removed in patients having surgery for breast cancer.

Authors:  J Michael Dixon; Julia Grewar; Dominique Twelves; Ashley Graham; Carlos Martinez-Perez; Arran Turnbull
Journal:  Breast Cancer Res Treat       Date:  2020-08-18       Impact factor: 4.872

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.